Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Key Highlights
- ➤Jaguar sponsors Abu Dhabi pediatric gastroenterology panel on intestinal failure therapies
- ➤Crofelemer studies show substantial reductions in weekly parenteral support needs
- ➤Jaguar expects MVID New Drug Application filing in mid-2027
- ➤Napo advances crofelemer development for rare intestinal failure diseases
SAN FRANCISCO, CA / ACCESS Newswire / October 6, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a sponsor of the 2nd Best of Elite Ped-GI meeting in Abu Dhabi in the United Arab Emirates and is also sponsoring a panel discussion titled Intestinal Barrier Beyond Total Parenteral Nutrition (TPN) on October 30, 2026 at the meeting. Participants in the panel discussion include Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, and Pravin Chaturvedi, PhD, Napo's and Jaguar's Chief Scientific Officer and Chair of the Scientific Advisory Board.
Dr. Miqdady is the Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi. He is also a Clinical Professor at Khalifa University's medical school in Abu Dhabi, and completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.
Get started
Create a free account to read the full story.